SEC Form 4 · accession 0001193125-26-385409
Artiva Biotherapeutics, Inc. · ARTV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alison Moore
Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 8, 2026 · 5:55 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817241
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $10.88 | Sep 8, 2026 | A | 13,750 | A | — | Sep 7, 2036 | Common Stock | 13,750 | 13,750 | D |
Explanation of responses
- F1The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.